Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 4/20 | 0.32 |
| ▸ | MDH1 | P40925 | 1/20 | 0.31 |
| ▸ | MDH2 | P40926 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3290103 | 0.89 | DPP8 (0.37) | PKMHSD11B1DPP8DPP9ALDH1A1 | |
| SCHEMBL7171010 | 0.86 | MAPT (0.33) | MAPT | |
| SCHEMBL22728354 | 0.85 | PKM (0.39) | PKMHSD11B1DPP8DPP9ALDH1A1 | |
| SCHEMBL1817331 | 0.84 | TSHR (0.39) | MAPTDPP4 | |
| SCHEMBL242186 | 0.83 | NAAA (0.39) | ALDH1A1NPSR1 | |
| SCHEMBL13015773 | 0.83 | PKM (0.37) | PKMHSD11B1DPP8DPP9ALDH1A1 | |
| SCHEMBL15281467 | 0.83 | PKM (0.37) | PKMHSD11B1DPP8DPP9ALDH1A1 | |
| SCHEMBL13383446 | 0.83 | PKM (0.37) | PKMHSD11B1DPP8DPP9ALDH1A1 | |
| SCHEMBL41045 | 0.83 | PKM (0.37) | PKMHSD11B1DPP8DPP9ALDH1A1 | |
| SCHEMBL5607853 | 0.82 | PKM (0.41) | PKMHSD11B1DPP8DPP9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103772252-B | Onium salt compound, acid amplifier derived therefrom, and resist composition comprising same | 锦湖石油化学株式会社 | 2017-01-11 | — | — | CN | disclosed |
| US-20100048757-A1 | ADAMANTANE DERIVATIVE, PROCESS FOR PRODUCTION THEREOF, RESIN COMPOSITION, AND CURED PRODUCT OF THE RESIN COMPOSITION | IDEMITSU KOSAN CO., LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2090564-A1 | ADAMANTANE DERIVATIVE, PROCESS FOR PRODUCTION THEREOF, RESIN COMPOSITION, AND CURED PRODUCT OF THE RESIN COMPOSITION | Idemitsu Kosan Co., Ltd. (JP) | 2009-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048757-A1 | ADAMANTANE DERIVATIVE, PROCESS FOR PRODUCTION THEREOF, RESIN COMPOSITION, AND CURED PRODUCT OF THE RESIN COMPOSITION | DNMT3A, PRMT5, MEP1A | PKM 4727/4885HSD11B1 822/4885DPP8 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.